Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated statistically significant and clinically meaningful improvement compared to placebo in all primary, key secondary, and secondary endpoints Denifanstat demonstrated a favorable safety and tolerability...
Read More Details
Finally We wish PressBee provided you with enough information of ( Ascletis Announces Phase III Trial of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne, Meets All Endpoints )
Also on site :
- Two Minors Admit to Felony Charges following Bomb and Shooting Threat at Ventura High School
- 2000s Rock Icon Makes Jaw-Dropping Career Move & Fans Are Here for It
- Dick Van Dyke, 99, and Wife Arlene Silver, 53, Still Have 'Plenty of Spark'